You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR FOSPHENYTOIN SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for fosphenytoin sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02920060 ↗ Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus Completed Institute of Medical Sciences of the Banaras Hindu University (BHU),India Phase 2 2015-01-01 This study is a randomized, open label, parallel group,comparing the safety and efficacy of valproate and levetiracetam in patients of age group 1 to 16 years with status epilepticus not responded to phenytoin and benzodiazepines approaching to pediatric emergency , IMS, BHU. The primary outcome measures will be Proportion of children in either group who have Cessation of all clinical seizure within 30 min of drug administration and secondary outcome will be time taken to control seizure (minutes) from the initiation of infusion. Proportion of children in either group who required additional drugs to abort ongoing clinical seizures, rates of adverse events (hypotension, bradycardia, respiratory depression, PICU stay, in hospital mortality) in the two groups were measured. Refractory status epilepticus condition is major pediatric neurological emergency with high mortality and morbidity. Till now, the treatment guidelines for it are based primarily on retrospective studies with very few randomized studies. There is lack of sufficient data to recommend one drug over another for treatment of refractory status epilepticus.
NCT02920060 ↗ Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus Completed Banaras Hindu University Phase 2 2015-01-01 This study is a randomized, open label, parallel group,comparing the safety and efficacy of valproate and levetiracetam in patients of age group 1 to 16 years with status epilepticus not responded to phenytoin and benzodiazepines approaching to pediatric emergency , IMS, BHU. The primary outcome measures will be Proportion of children in either group who have Cessation of all clinical seizure within 30 min of drug administration and secondary outcome will be time taken to control seizure (minutes) from the initiation of infusion. Proportion of children in either group who required additional drugs to abort ongoing clinical seizures, rates of adverse events (hypotension, bradycardia, respiratory depression, PICU stay, in hospital mortality) in the two groups were measured. Refractory status epilepticus condition is major pediatric neurological emergency with high mortality and morbidity. Till now, the treatment guidelines for it are based primarily on retrospective studies with very few randomized studies. There is lack of sufficient data to recommend one drug over another for treatment of refractory status epilepticus.
NCT05480553 ↗ A Phase 3 Study of NPC-06 in Patients With Pain Associated With Acute Herpes Zoster Not yet recruiting Nobelpharma Phase 3 2022-08-15 To confirm the pain relief effect and the safety of NPC-06 (fosphenytoin sodium hydrate) in patients with pain associated with acute herpes zoster in a placebo-controlled, double-blind, parallel-group, comparative manner.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for fosphenytoin sodium

Condition Name

Condition Name for fosphenytoin sodium
Intervention Trials
Acute Pain in Herpes Zoster 1
Grand Mal Status Epilepticus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for fosphenytoin sodium
Intervention Trials
Herpes Zoster 1
Herpes Simplex 1
Acute Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for fosphenytoin sodium

Trials by Country

Trials by Country for fosphenytoin sodium
Location Trials
Japan 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for fosphenytoin sodium

Clinical Trial Phase

Clinical Trial Phase for fosphenytoin sodium
Clinical Trial Phase Trials
Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for fosphenytoin sodium
Clinical Trial Phase Trials
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for fosphenytoin sodium

Sponsor Name

Sponsor Name for fosphenytoin sodium
Sponsor Trials
Nobelpharma 1
Institute of Medical Sciences of the Banaras Hindu University (BHU),India 1
Banaras Hindu University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for fosphenytoin sodium
Sponsor Trials
Other 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.